WO2024256956 - STABLE FORMULATIONS OF BILASTINE FOR NASAL AND OPHTHALMIC USE
National phase entry is expected:
Publication Number
WO/2024/256956
Publication Date
19.12.2024
International Application No.
PCT/IB2024/055686
International Filing Date
11.06.2024
Title **
[English]
STABLE FORMULATIONS OF BILASTINE FOR NASAL AND OPHTHALMIC USE
[French]
FORMULATIONS STABLES DE BILASTINE POUR UTILISATION NASALE ET OPHTALMIQUE
Applicants **
LEIUTIS PHARMACEUTICALS LLP
Inventors
KOCHERLAKOTA, Chandrashekhar
BANDA, Nagaraju
KESHIREDDY, Anji Reddy
PULLAGURA, Naga Udaya Sankar
Priority Data
202341040180
13.06.2023
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP India
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1958 | |
| EPO | Filing, Examination, Granting | 11845 | |
| Japan | Filing, Examination, Granting | 1959 | |
| South Korea | Filing, Examination, Granting | 1586 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
22,088
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention deals with the pharmaceutical formulations of bilastine and the methods of preparing such formulations for nasal and ophthalmic use. The formulations of present invention are stable and comprises of bilastine and other pharmaceutically acceptable excipients. These compositions may be used in treating different allergies and the associated conditions.[French]
La présente invention concerne les formulations pharmaceutiques de bilastine et les procédés de préparation de telles formulations pour une utilisation nasale et ophtalmique. Les formulations de la présente invention sont stables et comprennent de la bilastine et d'autres excipients pharmaceutiquement acceptables. Ces compositions peuvent être utilisées dans le traitement de différentes allergies et des affections associées.